China API Juggernaut Rolls On But Can India Recoup?
Executive Summary
Report: India’s huge dependence on Chinese active pharmaceutical ingredients (APIs), including in high disease burden areas, poses heightened risks to its health security and requires “urgent interventions.”
You may also be interested in...
Will India's APIs Incentive Scheme Galvanize Local Firms?
India shapes new production-linked incentives scheme for critical APIs to ensure self-reliance and cut massive dependence on imports from China, but much will depend on actual implementation, including timely clearances. Pharma will also need to 'walk the talk' alongside.
India APIs Incentive Scheme: Will It Galvanize Local Firms, Bridle The Dragon?
India shapes new production-linked incentives scheme for critical APIs to ensure self-reliance and cut massive dependence on imports from China, but much will depend on actual implementation, including timely clearances. Pharma will also need to 'walk the talk' alongside.
Coronavirus API Supply Impact A ‘Big Wake Up Call’ For India
Satish Reddy, president of the Indian Pharmaceutical Alliance and chair of Dr Reddy’s Laboratories, says that the government and domestic industry have to act promptly, and in tandem, to regain India’s glory days of dominance in active pharmaceutical ingredients and avoid a public health problem.